ClinicalTrials.gg
Not yet recruitingNCT05326087Updated Nov 9, 2026

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

A Phase 3 interventional study of GnRH antagonist and MPA in Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation and Polycystic Ovarian Syndrome, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Not yet recruiting. Open to female participants aged 20 Years to 37 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Phase 3, Interventional, and Treatment

How we know

Updated Nov 9, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
20 Years to 37 Years
Sex
Female
01

Study summary

This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:

Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.

PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.

The primary outcome is the euploidy rate of blastocysts.

02

Conditions studied

  • Preimplantation Genetic Testing
  • Progestin-primed Ovarian Stimulation
  • Polycystic Ovarian Syndrome
  • GnRH Antagonist
03

In context

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

This study's planned enrollment of 204 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.

Browse Polycystic Ovary Syndrome studies →

Lead sponsor

ShangHai Ji Ai Genetics & IVF Institute is the lead sponsor of 26 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women age between 20 and 37 years.
  • Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and/or ovarian volume >10 mL on transvaginal ultrasonographic scanning, and/or clinical/ biochemical hyperandrogenism. Other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded

Exclusion criteria

Exclusion Criteria:

  • Presence of a functional ovarian cyst with E2>100 pg/mL
  • Endometriosis grade 3 or higher
  • Repeated implantation failure (>=4 embryos replaced or >=2 blastocysts replaced without success)
  • Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)
  • Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;
  • Recipient of oocyte donation
  • Presence of hydrosalpinx which is not surgically treated
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (estimated)

Study arms

  • Active comparator
    Antagonist group

    Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.

    Drug: GnRH antagonist

  • Experimental
    PPOS group

    Women will receive oral MPA 10mg qd from Day 3 till the day of ovulation trigger.

    Drug: MPA

Interventions

06

What researchers measure

Primary outcomes

  1. euploidy rate

    euploidy rate of blastocysts

    Time frame: 1 month after oocyte retrieval

Secondary outcomes

  1. live birth rate

    deliveries ≥22 weeks gestation with heartbeat and breath of the first frozen embryo transfer

    Time frame: 1 year after embryo transfer

  2. cumulative live birth rate

    cumulative live birth within 6 months of randomization

    Time frame: 1 year after embryo transfer

  3. ongoing pregnancy

    a viable pregnancy beyond 12 weeks' gestation of the first frozen embryo transfer

    Time frame: 12 weeks' gestation

  4. number of oocytes retrieved

    number of oocytes retrieved

    Time frame: 1 day after oocyte retrieval

  5. OHSS(ovarian hyperstimulation syndrome)

    Moderate or severe ovarian hyperstimulation syndrome.Ovarian hyperstimulation syndrome (OHSS) is diagnosed and classified according to the Royal College of Obstetricians and Gynaecologists guideline. Green-top guideline No.5. Ovarian hyperstimulation syndrome. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg5/ (accessed 26 Feb 2016).

    Time frame: 1 month after ovarian stimulation

  6. birthweight of newborns

    birthweight of newborns

    Time frame: 1 year after embryo transfer

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Begueria R, Garcia D, Vassena R, Rodriguez A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod. 2019 May 1;34(5):872-880. doi: 10.1093/humrep/dez034. PubMed 30927417 ↗
  • Lee E, Illingworth P, Wilton L, Chambers GM. The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. Hum Reprod. 2015 Feb;30(2):473-83. doi: 10.1093/humrep/deu303. Epub 2014 Nov 28. PubMed 25432917 ↗
  • Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017 Mar 1;23(2):211-220. doi: 10.1093/humupd/dmw047. PubMed 28062551 ↗
  • Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022. Epub 2015 May 5. PubMed 25956370 ↗
  • Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):48-53. doi: 10.1210/jc.2005-1329. Epub 2005 Oct 25. PubMed 16249284 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results after deidentification (text, tables, figures, and appendices) and study protocol will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available when beginning 3 months and ending 5 years following article publication.

Access criteria: To achieve aims in the approved proposal, researchers who provide a methodologically sound proposal will be shared with. Proposals should be sent to lihe198900@163.com.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Dec 2028, 18 months later.

Of 26 non-industry phase 3 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 18 months is below that.

Counting every sponsor, half of 26 studies reached it within 28 months; a quarter within 11 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Jun 2026 → Jun 2027 and primary completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Apr 13, 2022
StartEst.
Jun 1, 2027was Jun 2026
Primary completionEst.
Dec 1, 2028was Dec 2027
CompletionEst.
Dec 1, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Jun 1, 2027
Nov 9, 2026
Primary completion
Dec 1, 2027→Dec 1, 2028
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Jun 1, 2026→Jun 1, 2027
    Primary completion Dec 1, 2027→Dec 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05326087
Lead sponsor
ShangHai Ji Ai Genetics & IVF Institute
Responsible party
Sponsor
First posted
Apr 13, 2022
Start date
Jun 1, 2027 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

HE LI, MD
Contact
lihe198900@163.com
+8613817223099
XIAOXI SUN, PHD
Contact
XIAOXI SUN, PHD
principal investigator · Shanghai JiAi Genetics & IVF Institute, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Medroxyprogesterone Acetate

Start the discussion